Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204478846> ?p ?o ?g. }
- W3204478846 endingPage "15" @default.
- W3204478846 startingPage "6" @default.
- W3204478846 abstract "Abstract Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need. Although there are several classes of dissimilar antidepressant drugs approved for MDD, the current drugs have either limited efficacy or are associated with undesirable side effects and withdrawal symptoms. The efficacy and side effects of antidepressant drugs are mainly attributed to their actions on different monoamine neurotransmitters (serotonin, norepinephrine, and dopamine). Development of new antidepressants with novel targets beyond the monoamine pathways may fill the unmet need in treatment of MDD and TRD. The recent approval of intranasal Esketamine (glutamatergic agent) in conjunction with an oral antidepressant for the treatment of adult TRD patients was the first step toward expanding beyond the monoamine targets. Several other glutamatergic (AXS-05, REL-1017, AV-101, SLS-002, AGN24175, and PCN-101) and GABAergic (brexanolone, zuranolone, and ganaxolone) drugs are currently in different stages of clinical development for MDD, TRD and other indications. The renaissance of psychedelic drugs and the emergence of preliminary positive clinical trial results with psilocybin, Ayahuasca, 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT), and lysergic acid diethylamide (LSD) may pave the way towards establishing this class of drugs as effective therapies for MDD, TRD and other neuropsychiatric disorders. Going beyond the monoamine targets appears to be an effective strategy to develop novel antidepressant drugs with superior efficacy, safety, and tolerability for the improved treatment of MDD and TRD." @default.
- W3204478846 created "2021-10-11" @default.
- W3204478846 creator A5030182773 @default.
- W3204478846 creator A5053181230 @default.
- W3204478846 creator A5069186555 @default.
- W3204478846 creator A5081640744 @default.
- W3204478846 date "2021-09-30" @default.
- W3204478846 modified "2023-10-18" @default.
- W3204478846 title "Novel antidepressant drugs: Beyond monoamine targets" @default.
- W3204478846 cites W125676077 @default.
- W3204478846 cites W1561342581 @default.
- W3204478846 cites W173089895 @default.
- W3204478846 cites W1746596066 @default.
- W3204478846 cites W1915010695 @default.
- W3204478846 cites W1966424565 @default.
- W3204478846 cites W1967145875 @default.
- W3204478846 cites W1969070039 @default.
- W3204478846 cites W1978697775 @default.
- W3204478846 cites W1980049394 @default.
- W3204478846 cites W1987266621 @default.
- W3204478846 cites W1990168531 @default.
- W3204478846 cites W1993904321 @default.
- W3204478846 cites W1996780673 @default.
- W3204478846 cites W1997232706 @default.
- W3204478846 cites W1999081857 @default.
- W3204478846 cites W2018114814 @default.
- W3204478846 cites W2023081218 @default.
- W3204478846 cites W2024278554 @default.
- W3204478846 cites W2027061717 @default.
- W3204478846 cites W2049022403 @default.
- W3204478846 cites W2057387160 @default.
- W3204478846 cites W2057823239 @default.
- W3204478846 cites W2060150052 @default.
- W3204478846 cites W2074907255 @default.
- W3204478846 cites W2078821747 @default.
- W3204478846 cites W2086126018 @default.
- W3204478846 cites W2089694151 @default.
- W3204478846 cites W2094957254 @default.
- W3204478846 cites W2104460069 @default.
- W3204478846 cites W2109334244 @default.
- W3204478846 cites W2127483997 @default.
- W3204478846 cites W2154223842 @default.
- W3204478846 cites W2157040702 @default.
- W3204478846 cites W2162933869 @default.
- W3204478846 cites W2168253623 @default.
- W3204478846 cites W2172129050 @default.
- W3204478846 cites W2257443024 @default.
- W3204478846 cites W2265316152 @default.
- W3204478846 cites W2291443053 @default.
- W3204478846 cites W2330587564 @default.
- W3204478846 cites W2343005918 @default.
- W3204478846 cites W2373469551 @default.
- W3204478846 cites W2419844652 @default.
- W3204478846 cites W2579967741 @default.
- W3204478846 cites W2588649755 @default.
- W3204478846 cites W2598012653 @default.
- W3204478846 cites W2762746674 @default.
- W3204478846 cites W2762798648 @default.
- W3204478846 cites W2767530231 @default.
- W3204478846 cites W2779386549 @default.
- W3204478846 cites W2790275773 @default.
- W3204478846 cites W2796940952 @default.
- W3204478846 cites W2889166554 @default.
- W3204478846 cites W2889396010 @default.
- W3204478846 cites W2895589451 @default.
- W3204478846 cites W2900937351 @default.
- W3204478846 cites W2914255920 @default.
- W3204478846 cites W2916664976 @default.
- W3204478846 cites W2919995896 @default.
- W3204478846 cites W2925451033 @default.
- W3204478846 cites W2948816951 @default.
- W3204478846 cites W2950701273 @default.
- W3204478846 cites W2952169207 @default.
- W3204478846 cites W2954247402 @default.
- W3204478846 cites W2961020354 @default.
- W3204478846 cites W2964775179 @default.
- W3204478846 cites W2970683278 @default.
- W3204478846 cites W2972149772 @default.
- W3204478846 cites W2981272605 @default.
- W3204478846 cites W2982430136 @default.
- W3204478846 cites W2986257172 @default.
- W3204478846 cites W2990240756 @default.
- W3204478846 cites W2996870046 @default.
- W3204478846 cites W3003830815 @default.
- W3204478846 cites W3007521094 @default.
- W3204478846 cites W3007923795 @default.
- W3204478846 cites W3012444575 @default.
- W3204478846 cites W3015140823 @default.
- W3204478846 cites W3017383621 @default.
- W3204478846 cites W3034622008 @default.
- W3204478846 cites W3040446518 @default.
- W3204478846 cites W3046057820 @default.
- W3204478846 cites W3046100757 @default.
- W3204478846 cites W3085641834 @default.
- W3204478846 cites W3088338988 @default.
- W3204478846 cites W3090852378 @default.
- W3204478846 cites W3092669895 @default.
- W3204478846 cites W3133808595 @default.